
    
      This study was a single centre, open-label, pharmacokinetic, randomized cross-over study in
      healthy male volunteers and post-menopausal women. This study was conducted over three
      different cohorts as follows:

      Cohort 1: Subjects received a single 800 mg (as free base) dose of five different treatment
      regimes (treatments A, B, C, D and E) on five occasions.

      Cohort 2: Subjects received a single 800 mg (as free base) dose of four different treatment
      regimes (treatments F, G, H and I) on four occasions.

      Cohort 3: Subjects received a single dose, 800mg (as free base) of prototype solution
      formulation 1 (treatment J) and 400mg (as free base) of prototype solution formulation 1
      (treatment K) on two occasions. The treatments were administered under the fasted state.
    
  